<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01337427</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00028117</org_study_id>
    <nct_id>NCT01337427</nct_id>
  </id_info>
  <brief_title>Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis</brief_title>
  <official_title>Optical Coherence Tomography (OCT) in a Multicenter, Randomized,Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <brief_summary>
    <textblock>
      This research sub-study is being completed as a part of the Multicenter, Randomized,
      Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of
      PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple Sclerosis
      (Protocol #: NA_00028117). This substudy is being done to understand the efficacy of BIIB017
      by measuring the nerve fiber thickness in the eye.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The study was not feasible to conduct in the US and abroad.
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the proportion of patients with RNFL decrease of 5 microns or more from baseline to month 12 in the BIIB-17 vs. placebo arms.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the proportion of patients with RNFL decrease of 5 microns or more from baseline to month 24 in the BIIB-17 vs. placebo arms.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of proportion of patients with a decrease of &gt;10 percent of baseline value in any RNFL quadrant from baseline to month 12 in the BIIB-17 vs. placebo arms.</measure>
    <time_frame>baseline and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of decrease between baseline scans and 3 month scan (to examine for pseudoatrophy) in this study population.</measure>
    <time_frame>baseline and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of decrease between 3 month scans (mean and/or quadrant) and follow up scans (12 months) in this study population.</measure>
    <time_frame>3 months and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of macular volume decreases from baseline or 3 months to follow up scans at 12 months in this study population.</measure>
    <time_frame>baseline and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of retinal nuclear layer decreases from baseline or 3 months to follow up scan at 12 months in this study population.</measure>
    <time_frame>baseline and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the above OCT parameters in patients with optic neuritis or history of optic neuritis.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of proportion of patients with a decrease of &gt;10 percent of baseline value in any RNFL quadrant from baseline to month 24 in the BIIB-17 vs. placebo arms.</measure>
    <time_frame>baseline and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of decrease between 3 month scans (mean and/or quadrant) and follow up scans (24 months) in this study population.</measure>
    <time_frame>3 months and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of macular volume decreases from baseline or 3 months to follow up scans at 24 months in this study population.</measure>
    <time_frame>baseline and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of retinal nuclear layer decreases from baseline or 3 months to follow up scan at 24 months in this study population.</measure>
    <time_frame>baseline and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the above OCT parameters in patients with optic neuritis or history of optic neuritis.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Placebo for 48 weeks, BIIB017 for 48 weeks</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo every 2 weeks for 48 weeks followed by 125 mcg BIIB017 SC every 2 or 4 weeks for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIIB017 every 2 weeks for 96 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>125 mcg BIIB017 SC every 2 weeks for 96 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIIB017 every 4 weeks for 96 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>125 mcg BIIB017 SC every 4 weeks for 96 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB017</intervention_name>
    <description>BIIB017 is supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 mcg dose) of 20 kDa mPEG-O-2-methylpropionaldehyde-modified human IFN β-1a in 20 mM acetic acid/sodium acetate buffer pH 4.8, 150 mM arginine hydrochloride, and 0.005% Polysorbate 20.</description>
    <arm_group_label>Placebo for 48 weeks, BIIB017 for 48 weeks</arm_group_label>
    <arm_group_label>BIIB017 every 2 weeks for 96 weeks</arm_group_label>
    <arm_group_label>BIIB017 every 4 weeks for 96 weeks</arm_group_label>
    <other_name>PEGylated Interferon beta-1a</other_name>
    <other_name>PEG IFN β-1a</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to understand the purpose and risks of the study and provide signed and dated
             informed consent and authorization to use protected health information (PHI) in
             accordance with national and local subject privacy regulations.

          -  A participant in the ADVANCE study aged 18 to 55 years old, inclusive, at the time of
             informed consent

        Exclusion Criteria:

          -  As per the ADVANCE main study

          -  History of intraocular surgery, retinal disease, glaucoma, or diabetes

          -  Refractive errors of more than ±6.0 diopters

          -  Inability to tolerate OCT procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Calabresi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2011</study_first_submitted>
  <study_first_submitted_qc>April 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2011</study_first_posted>
  <last_update_submitted>September 12, 2014</last_update_submitted>
  <last_update_submitted_qc>September 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2014</last_update_posted>
  <responsible_party>
    <name_title>Peter Calabresi, MD</name_title>
    <organization>Johns Hopkins University</organization>
  </responsible_party>
  <keyword>multiple sclerosis</keyword>
  <keyword>relapsing</keyword>
  <keyword>MS</keyword>
  <keyword>injectable</keyword>
  <keyword>subcutaneous</keyword>
  <keyword>SC</keyword>
  <keyword>PEGylated</keyword>
  <keyword>interferon</keyword>
  <keyword>PEG</keyword>
  <keyword>OCT</keyword>
  <keyword>Optical Coherence Tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

